Inmed Pharmaceuticals Stock Price, News & Analysis

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a pharmaceutical drug development company whose core focus is developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs. According to the company’s public disclosures, its research programs target the CB1/CB2 receptors and are concentrated in three main therapeutic areas: Alzheimer’s disease, ocular conditions and dermatological indications.

Business focus and operating segments

InMed describes itself as a pharmaceutical drug development company with operations that include both pharmaceutical R&D and a commercial business through its subsidiary BayMedica. The company’s programs are based on proprietary small molecules that target CB1/CB2 receptors, and its pipeline consists of three separate programs in Alzheimer’s, ocular and dermatological indications. In addition, InMed has a commercial segment through BayMedica that is involved in rare, non-intoxicating cannabinoids.

InMed’s operations have been reported in two operating segments in prior descriptions: the InMed Pharma segment, which is organized around the research and development of small molecule pharmaceutical drug candidates, and the BayMedica Commercial segment, which is organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. The company has stated that, together with BayMedica, it is involved in the manufacturing, development and commercialization of products based on rare cannabinoids and proprietary small molecule drug analogs.

Therapeutic pipeline

InMed’s pipeline is centered on three drug development programs in the treatment of Alzheimer’s, ocular and dermatological indications. Public materials describe these as proprietary small molecule drug candidates targeting CB1/CB2 receptors.

INM-901 – Alzheimer’s disease: INM-901 is described as a proprietary small molecule drug candidate under development for the treatment of Alzheimer’s disease. Company communications state that INM-901 targets multiple biological pathways associated with Alzheimer’s disease pathology and is being advanced as a potential treatment through multiple mechanisms of action. InMed has reported preclinical data in a well-established 5xFAD Alzheimer’s disease mouse model, including assessments of hippocampal RNA expression, inflammatory markers, immunohistochemistry and behavioral outcomes after long-term treatment. The company has highlighted findings such as reductions in neuroinflammation markers, changes in amyloid-beta immunoreactivity, and trends in behavioral measures related to cognition, anxiety-related behavior and sensory responsiveness in preclinical studies.

InMed has also reported pharmacokinetic work for INM-901, including studies in large animal models and preclinical evaluations of drug delivery. Company disclosures indicate that INM-901 can be administered orally while achieving therapeutic brain levels comparable to intraperitoneal injection in an in vivo model. InMed has also referenced molecular data, including mRNA expression, that it states are aligned with observed behavioral findings in preclinical work.

INM-089 – Ocular indications: INM-089 is described by the company as a proprietary small molecule drug candidate under investigation for the treatment of dry age-related macular degeneration (AMD). Public updates state that InMed is conducting preclinical studies that have demonstrated functional and pathological changes in a dry AMD disease study model. The company has also reported the selection of an intravitreal formulation for INM-089 and has disclosed that this formulation has been delivered to the targeted area of the eye in preclinical studies at doses that are multiples of a calculated safety margin relative to an intended therapeutic dose.

Dermatological program: InMed states that its pipeline includes a dermatological program among its three separate programs in Alzheimer’s, ocular and dermatological indications. Earlier descriptions have referenced INM-755 as a product candidate for epidermolysis bullosa, and company materials continue to refer to a dermatological indication as one of its three core program areas.

Rare cannabinoid commercial activities (BayMedica)

InMed’s wholly owned subsidiary BayMedica is described as a commercial business focusing on rare, non-intoxicating cannabinoids. Public disclosures characterize BayMedica as a supplier of non-intoxicating rare cannabinoids to the health and wellness sector and as part of a commercial segment that manufactures and commercializes bulk rare cannabinoids as ingredients. InMed has reported that BayMedica generated sales and has discussed revenue trends, pricing adjustments and cost of goods sold in its financial statements and management discussion and analysis.

The company has also disclosed that recent U.S. legislation, specifically H.R. 5371, the “Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026,” could have a material negative impact on aspects of BayMedica’s commercial business and its inventory of rare, non-intoxicating cannabinoids if certain provisions come into force in their current form. InMed has stated that BayMedica is evaluating alternative supply chain options to maintain regulatory compliance, and that BayMedica is continuing to operate its business in the normal course while it assesses potential options.

Corporate structure, listing and jurisdiction

InMed Pharmaceuticals Inc. is incorporated in British Columbia, Canada. The company’s common shares, with no par value, are listed on The Nasdaq Stock Market LLC under the trading symbol INM, as indicated in its SEC filings. InMed has identified itself as an emerging growth company under applicable U.S. securities regulations.

Research, development and regulatory pathway

InMed states that its pharmaceutical drug development programs operate within the traditional drug approval pathway under U.S. Food and Drug Administration (FDA) guidance. Company disclosures describe ongoing preclinical work, Chemistry, Manufacturing and Controls (CMC) activities, and preparations for regulatory interactions such as a pre-IND meeting and IND-enabling studies to support an Investigational New Drug (IND) submission for INM-901. InMed’s public communications also reference intellectual property efforts, including filing an international patent application under the Patent Cooperation Treaty covering pharmaceutical composition and methods of use for INM-901 in neurodegenerative diseases, including Alzheimer’s disease.

The company has also described the use of scientific advisory input, including the appointment of external experts to its scientific advisory board, to support its Alzheimer’s disease program and broader neurodegenerative disease strategy.

Financial reporting and governance

InMed files annual and quarterly financial statements, management’s discussion and analysis, and other reports with the U.S. Securities and Exchange Commission (SEC) and Canadian securities regulators. These filings include consolidated financial statements covering both the pharmaceutical development activities and the BayMedica commercial segment. The company has reported items such as sales from BayMedica, research and development expenses, general and administrative expenses, and cash and cash equivalents in its public financial statements.

InMed holds an annual general and special meeting of shareholders, at which shareholders vote on matters such as the election of directors, the appointment of auditors and specific share issuance proposals. Recent proxy and 8-K filings describe the election of directors, approval of CBIZ CPAs P.C. as the independent registered public accounting firm, and shareholder approval of the potential issuance of 20% or more of the company’s common shares pursuant to a Standby Equity Purchase Agreement, in accordance with Nasdaq Listing Rules. The company has also disclosed appointments of new board members with experience in pharmaceuticals, biotechnology, corporate development and capital markets.

Risk disclosures and forward-looking information

In its press releases and SEC filings, InMed includes cautionary notes regarding forward-looking information. The company identifies that its statements about future development plans, regulatory approvals, legislative changes, financial performance and other matters are subject to known and unknown risk factors. InMed directs readers to its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings available on the SEC’s website for a detailed discussion of risks and uncertainties affecting its business, including those related to its pharmaceutical pipeline and BayMedica’s commercial operations.